---
title: "EyePoint (EYPT) news: layoffs"
url: "https://aibio.space/companies/eyepoint/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "EYPT layoffs news. EyePoint news for investors: EyePoint develops Duravyu, a slow-release eye insert of the drug vorolanib meant to replace frequent…"
---

Desk view · Opinion · Updated Oct 22, 2026

## EyePoint's Duravyu now rests on diabetic macular edema

EyePoint showed Duravyu can cut injections but not that it matches aflibercept on vision, and two wet AMD failures have shrunk the company to a single DME bet. The DME readout in the fourth quarter of 2027 decides the story, and cash is the constraint until then.

Read the full desk view

aibio.space Investor Rank · Opinion

**1** /10 Most negative view

Duravyu missed vision non-inferiority twice in wet AMD, leaving one DME bet on the same design in late 2027 with about $118 million and half the staff gone.

- **Technology**: 0/2

- **Odds**: 0/2

- **Balance sheet**: 0/2

- **Risk**: 0/2

- **Momentum**: 0/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Durable but not equal.** Duravyu cut injections by about 40% but missed vision non-inferiority to aflibercept in two wet AMD phase 3 trials.

- **Odds**: **Below base rates.** The DME trials use the same non-inferiority design that failed twice in wet AMD, against a 52.4% general approval rate from phase 3.

- **Balance sheet**: **Thin for the wait.** About $118 million at September 30 against DME data in the fourth quarter of 2027, after a 53% staff cut.

- **Main risk**: **A third phase 3 miss.** COMO and CAPRI test the same drug and dose against aflibercept on vision.

- **Watch next**: **DME topline in late 2027.** Before then, updated runway guidance and any financing or partnering.

## Top news on EyePoint

1. 2026-10-19 Distress [EyePoint cuts about half its staff after second Duravyu wet AMD phase 3 miss](https://aibio.space/news/eyepoint-cuts-about-half-staff-after-second-duravyu-wet-amd-phase-3/) Lucia missed its non-inferiority goal against Eylea. EyePoint will end both wet AMD trials early and put its cash behind two diabetic macular edema studies due in late 2027.

## Dates

**Fourth quarter of 2027**
Topline 56-week data from phase 3 DME trials COMO and CAPRI [Source](https://www.sec.gov/Archives/edgar/data/0001314102/000119312526424644/eypt-ex99_1.htm)

**Fourth quarter of 2026 to first half of 2027**
About 53% workforce reduction, most in Q4 2026, for about $30 million in annual savings [Source](https://finviz.com/news/403991/eyepoint-announces-53-workforce-reduction-following-phase-3-duravyu-trial-results)

**Not dated**
Additional analyses of LUCIA and pooled phase 3 data to decide next steps in wet AMD [Source](https://www.sec.gov/Archives/edgar/data/0001314102/000119312526424644/eypt-ex99_1.htm)

## The money

About $118 million in cash, cash equivalents and short-term investments at September 30, 2026 (Q3 2026). August guidance of runway into Q4 2027 predates the October restructuring; no updated runway found. [Source](https://www.ophthalmologytimes.com/view/duravyu-misses-noninferiority-end-point-in-phase-3-lucia-wet-amd-trial)

Total net revenue of $0.5 million in Q2 2026, down from $5.3 million, after deferred revenue from the 2023 YUTIQ license was fully recognized. [Source](https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-q2-2026-results-and-developments)

## Risks on the record

- Duravyu missed vision non-inferiority to aflibercept in both wet AMD phase 3 trials; the DME trials use the same comparator and endpoint type. [Source](https://www.ophthalmologytimes.com/view/duravyu-misses-noninferiority-end-point-in-phase-3-lucia-wet-amd-trial)
- Cash of about $118 million at September 30, 2026 must last to DME data in Q4 2027. [Source](https://www.ophthalmologytimes.com/view/duravyu-misses-noninferiority-end-point-in-phase-3-lucia-wet-amd-trial)
- Conjunctival hemorrhage, vitreous floaters and retinal hemorrhage were more common with Duravyu than aflibercept in LUCIA. [Source](https://www.ophthalmologytimes.com/view/duravyu-misses-noninferiority-end-point-in-phase-3-lucia-wet-amd-trial)

## Questions investors ask

### What is aibio.space's Investor Rank for EyePoint?

1 out of 10, our most negative view. Duravyu missed vision non-inferiority twice in wet AMD, leaving one DME bet on the same design in late 2027 with about $118 million and half the staff gone. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### Did EyePoint's Duravyu pass its wet AMD phase 3 trials?

No. LUGANO missed non-inferiority to aflibercept in its full dataset in August 2026, and LUCIA missed in October 2026, with Duravyu eyes gaining 2.5 letters against 6.1 for aflibercept. [Source](https://www.ophthalmologytimes.com/view/duravyu-misses-noninferiority-end-point-in-phase-3-lucia-wet-amd-trial)

### What is EyePoint doing after the LUCIA failure?

On October 19, 2026, EyePoint said it would cut about 53% of its workforce, mostly in the fourth quarter of 2026, for about $30 million in annual savings. It is focusing on Duravyu in diabetic macular edema. [Source](https://finviz.com/news/403991/eyepoint-announces-53-workforce-reduction-following-phase-3-duravyu-trial-results)

### When will EyePoint report its DME phase 3 results?

Topline data from the COMO and CAPRI trials of Duravyu in diabetic macular edema are expected in the fourth quarter of 2027. [Source](https://www.sec.gov/Archives/edgar/data/0001314102/000119312526424644/eypt-ex99_1.htm)

### How much cash does EyePoint have?

EyePoint reported about $118 million in cash, cash equivalents and short-term investments at September 30, 2026, down from $180 million at June 30. [Source](https://www.ophthalmologytimes.com/view/duravyu-misses-noninferiority-end-point-in-phase-3-lucia-wet-amd-trial)

### What is Duravyu?

Duravyu is vorolanib, a tyrosine kinase inhibitor, in a bioerodible insert injected into the eye and re-dosed every six months. It is investigational and licensed from Equinox Sciences for use outside greater China. [Source](https://app.edgar.tools/filing/1314102/0001193125-26-207537/eypt-ex99_1.htm)

### What is the latest EyePoint (EYPT) stock news?

Our latest story on EyePoint, dated Oct 19, 2026: "EyePoint cuts about half its staff after second Duravyu wet AMD phase 3 miss". Lucia missed its non-inferiority goal against Eylea. EyePoint will end both wet AMD trials early and put its cash behind two diabetic macular edema studies due in late 2027. [Source](https://aibio.space/news/eyepoint-cuts-about-half-staff-after-second-duravyu-wet-amd-phase-3/)

### Is EyePoint in financial distress?

Our latest distress story, dated Oct 19, 2026: "EyePoint cuts about half its staff after second Duravyu wet AMD phase 3 miss". Lucia missed its non-inferiority goal against Eylea. EyePoint will end both wet AMD trials early and put its cash behind two diabetic macular edema studies due in late 2027. [Source](https://aibio.space/news/eyepoint-cuts-about-half-staff-after-second-duravyu-wet-amd-phase-3/)

### What is EyePoint's market cap?

We do not publish live share prices. In its annual report, EyePoint, Inc. put the market value of shares held by non-affiliates (public float) at $642.6 million as of Jun 30, 2025. Source

### Is EyePoint a smaller reporting company?

SEC records list EyePoint, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company. Source

### Where is EyePoint headquartered?

SEC records list its business address as 480 PLEASANT STREET, WATERTOWN, MA, 02472. Source

### When does EyePoint's fiscal year end?

EyePoint, Inc.'s fiscal year ends on December 31, per SEC records. Source

### What did EyePoint last file with the SEC?

Its most recent filing in our record is an 8-K filed 2026-10-19. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-20261017.htm)

### What was EyePoint called before?

SEC records list these former names: EyePoint Pharmaceuticals, Inc.; pSivida Corp.; pSivida LTD. Source

### What industry is EyePoint in?

Its SEC industry code (SIC 3826) is Laboratory Analytical Instruments. Source

## Legal and investor matters

Checked against EyePoint filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

EyePoint's 10-Q filed 2026-08-05 (Note 12, Contingencies, Legal Proceedings) says the company is subject to various routine legal proceedings and claims incidental to its business, which management believes will not have a material effect. The same note describes a settlement with the U.S. Department of Justice, and the 10-Q describes EyePoint's complaint against Ocular Therapeutix. [Source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm)

1. 2026-10-19 Other EyePoint plans about 53% workforce cut after LUCIA Phase 3 results EyePoint's board approved a strategic prioritization plan on 2026-10-17, after reviewing topline results from LUCIA, the second pivotal Phase 3 trial of DURAVYU in wet AMD. The plan includes concluding the pivotal Phase 3 wet AMD trials early and reducing the workforce by about 53%, to focus resources on DURAVYU in diabetic macular edema. EyePoint estimates aggregate charges of about $9 million related to employee separation benefits, including severance. [EyePoint Form 8-K filed 2026-10-19](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-20261017.htm)
2. 2026-07-17 Regulatory EyePoint settles DOJ False Claims Act probe over DEXYCU for $4.68 million EyePoint settled with the U.S. Department of Justice, HHS-OIG, the Defense Health Agency and a qui tam relator over alleged False Claims Act violations tied to sales, marketing and sampling practices for DEXYCU, which it sold from 2019 to 2023. It agreed to pay $4,678,981.86 plus interest and signed a five-year Corporate Integrity Agreement with HHS. The settlement is not an admission of liability. EyePoint paid on 2026-07-31. U.S. District Court for the District of Massachusetts · Status: settled [EyePoint Form 8-K filed 2026-07-17](https://www.sec.gov/Archives/edgar/data/1314102/000119312526307792/eypt-20260713.htm)
3. 2026-03-20 Litigation EyePoint sues Ocular Therapeutix in Massachusetts state court EyePoint says that on 2026-03-20 it filed a complaint against Ocular Therapeutix in Middlesex County Superior Court in Massachusetts. The complaint alleges Ocular disseminated false or misleading representations about EyePoint and the clinical results of DURAVYU. It asserts defamation, commercial disparagement, Chapter 93A and tortious interference claims. Ocular filed its answer on 2026-04-13 seeking dismissal with prejudice. Middlesex County Superior Court, Massachusetts · Status: pending [EyePoint Form 10-Q filed 2026-08-05](https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm)
4. 2025-10-14 Financing EyePoint prices public offering of 11 million shares at $12.00 EyePoint entered into an underwriting agreement on 2025-10-14 for 11,000,000 shares at $12.00 per share, plus pre-funded warrants for 1,500,000 shares at $11.999. Underwriters held a 30-day option for up to 1,875,000 more shares. The company reported net proceeds of about $141 million and said it would fund DURAVYU development in wet AMD and diabetic macular edema. The offering closed on 2025-10-16. [EyePoint Form 8-K filed 2025-10-17](https://www.sec.gov/Archives/edgar/data/1314102/000119312525241639/d98837d8k.htm)
5. 2024-10-29 Financing EyePoint prices public offering of 12.7 million shares at $11.00 EyePoint entered into an underwriting agreement on 2024-10-29 for 12,727,273 shares at $11.00 per share with J.P. Morgan as representative. Underwriters exercised in full their option for 1,909,090 additional shares on 2024-10-30. Net proceeds including the option were about $151.1 million, and the offering closed on 2024-10-31. EyePoint said it would fund DURAVYU development in wet AMD and diabetic macular edema. [EyePoint Form 8-K filed 2024-10-31](https://www.sec.gov/Archives/edgar/data/1314102/000119312524248694/d904414d8k.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Duravyu (vorolanib intravitreal insert) | Wet AMD | Phase 3 LUGANO and LUCIA missed primary endpoints; trials being ended early [Source](https://www.ophthalmologytimes.com/view/duravyu-misses-noninferiority-end-point-in-phase-3-lucia-wet-amd-trial) |
| Duravyu, COMO trial | Diabetic macular edema | Phase 3, fully enrolled; topline Q4 2027 [Source](https://www.sec.gov/Archives/edgar/data/0001314102/000119312526424644/eypt-ex99_1.htm) |
| Duravyu, CAPRI trial | Diabetic macular edema | Phase 3, fully enrolled; topline Q4 2027 [Source](https://www.sec.gov/Archives/edgar/data/0001314102/000119312526424644/eypt-ex99_1.htm) |
| Vorolanib IL-6 and JAK1 activity | Retinal disease (mechanism research) | Preclinical (ARVO 2026) [Source](https://app.edgar.tools/filing/1314102/0001193125-26-207537/eypt-ex99_1.htm) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

EyePoint's releases state the primary endpoint misses but leave the vision gap and safety rates to the slides

Both wet AMD phase 3 trials missed their primary vision endpoint, and the releases state the misses but pair them with secondary measures, an ad hoc analysis and nominal p-values. The actual vision gap, the side effect imbalances and the small size of the phase 2 trial behind the DME bet are in the filed slide deck and the trial registry, not the release text. The legal record is documented: a DOJ settlement, paid in July, with a five-year integrity agreement, an FDA warning letter from July 2024, and a suit EyePoint filed against Ocular Therapeutix.

1. Press release vs filing · weight high LUCIA release states the miss but not the letter gap **The company said:** "In LUCIA, despite demonstrating visual improvement, DURAVYU did not achieve the primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity (BCVA) versus on-label 2 mg aflibercept control." [source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm) **The record says:** The slide deck filed with the same 8-K shows the primary endpoint: "Aflibercept 2 mg q8W +6.1 letters DURAVYU 2.7 mg q24W +2.5 letters Difference -3.7 letters", on a slide marked as preliminary data pending final analysis. [source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm) **Our view:** The slide shows a 3.7 letter difference against aflibercept and says the confidence interval is outside the 4.5 letter non-inferiority margin. The release says non-inferiority was not achieved but does not give the difference or the margin, so readers of the release alone do not see how large the gap was.
2. Science · weight high LUGANO headline rested on an ad hoc analysis **The company said:** "DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients)" [source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm) **The record says:** The registry entry for the identical LUCIA design lists the primary outcome (the LUGANO entry, NCT06668064, lists the same) as "Average change in best corrected visual acuity (BCVA)" at "Weeks 52 and 56", with no exclusion rule described there. Two months later the LUCIA release said: "LUGANO also did not meet the primary endpoint in its full dataset". [source](https://clinicaltrials.gov/study/NCT06683742) **Our view:** Excluding nine patients in an analysis the release itself calls ad hoc is a post hoc result, and the August release led with it, though the same headline says the primary endpoint was not achieved in the full dataset. LUCIA then missed, and its release and deck do not offer a similar excluded cohort, which weakens the case that the LUGANO miss was a one-off.
3. Science · weight high DME bet leans on a 27-patient phase 2 **The company said:** "The DME program is supported by the positive Phase 2 VERONA data showing sustained visual acuity and over 70% of patients supplement-free for six months." [source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm) **The record says:** ClinicalTrials.gov lists VERONA (NCT06099184) with 27 patients enrolled across three arms, masking "Single (Participant)", and a primary outcome of "Time to first supplemental aflibercept injection" at Week 24. The phase 3 COMO trial's primary outcome is BCVA change "to the average of Weeks 52 and 56". The filed deck's VERONA slide adds: "Data excludes one outlier patient." [source](https://clinicaltrials.gov/study/NCT06099184) **Our view:** VERONA tested a different endpoint over less than half the follow-up, in a trial of about nine patients per arm. The DME phase 3 trials use the same BCVA non-inferiority test against aflibercept that both wet AMD trials failed.
4. Press release vs filing · weight medium "Favorable safety" next to an AE imbalance **The company said:** "Continued favorable safety profile for DURAVYU with redosing" [source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm) **The record says:** The filed deck's pooled table of ocular adverse events through Week 56 shows, for DURAVYU (n=443) versus aflibercept (n=464): vitreous floaters 8.6% vs 2.8%, neovascular age-related macular degeneration 5.9% vs 1.7%, retinal haemorrhage 4.7% vs 1.5%, vitreous haemorrhage 2.3% vs 0.0%. [source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm) **Our view:** The deck reports no cases of insert migration or retinal vasculitis, and severe intraocular inflammation and endophthalmitis under 1% in both arms, but it also shows more floaters, bleeding and neovascular AMD events on DURAVYU. A doctor choosing between this and aflibercept would want those rates, and the release summarizes them as favorable.
5. Press release vs filing · weight medium Runway not restated after the cut **The company said:** "EyePoint estimates that it had approximately $118 million in cash, cash equivalents, and short-term investments as of September 30, 2026." [source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm) **The record says:** The 10-Q said "cash, cash equivalents, and investments in marketable securities of $180.5 million" at June 30, 2026 would "fund our operations into the fourth quarter of 2027" and added "there is no assurance that additional funding will be achieved". The October release and 8-K give no updated runway; DME topline is guided to the fourth quarter of 2027. [source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm) **Our view:** The September 30 estimate is about $62 million below the June 30 figure, the company expects annualized savings of about $30 million, and it plans about $9 million in severance and related charges. The 10-Q runway ended in the same quarter as the DME readout, and the October release and 8-K do not restate it.
6. Legal and disclosure record · weight low DOJ settlement, integrity agreement, warning letter **The record says:** The 10-Q states that on July 17, 2026 the company settled a DOJ False Claims Act and Anti-Kickback Statute investigation tied to DEXYCU for $4,678,981.86 plus interest, entered a five-year Corporate Integrity Agreement with HHS on July 13, 2026, and paid in full on July 31, 2026. It also discloses the FDA warning letter received in July 2024 on YUTIQ manufacturing at the Watertown facility, and a defamation suit EyePoint filed against Ocular Therapeutix in Middlesex County Superior Court on March 20, 2026. No securities class action or derivative suit is disclosed in the latest filing. [source](https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm) **Our view:** These matters are disclosed and the DOJ one is paid, but the integrity agreement adds compliance cost for five years. The 10-Q says the company has fully executed its corrective and preventive action plan for the warning letter.

Documents we compared

- [Press release: LUCIA topline results (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm) 2026-10-19
- [LUCIA topline slide deck (8-K Ex. 99.2)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm) 2026-10-19
- [Press release: strategic prioritization (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm) 2026-10-19
- [8-K Items 2.02 and 2.05, strategic prioritization](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-20261017.htm) 2026-10-19
- [Press release: LUGANO topline results (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm) 2026-08-17
- [LUGANO expanded analyses deck (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm) 2026-09-10
- [Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm) 2026-08-05
- [ClinicalTrials.gov NCT06683742 (LUCIA)](https://clinicaltrials.gov/study/NCT06683742) 2026-09-03
- [ClinicalTrials.gov NCT06099184 (VERONA)](https://clinicaltrials.gov/study/NCT06099184) 2026-10-23
- [ClinicalTrials.gov NCT07449936 (COMO)](https://clinicaltrials.gov/study/NCT07449936) 2026-10-02

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:EYPT on TradingView](https://www.tradingview.com/symbols/NASDAQ-EYPT/).

## SEC filings and registration

- **SEC name**: EyePoint, Inc.

- **CIK**: 1314102

- **Industry (SIC)**: Laboratory Analytical Instruments (3826)

- **US tickers**: EYPT (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 480 PLEASANT STREET, WATERTOWN, MA, 02472

- **Phone**: 617-926-5000

- **Shares outstanding**: 86,212,138 as of 2026-07-31 (10-Q filed 2026-08-05)

- **Former names**: EyePoint Pharmaceuticals, Inc.; pSivida Corp.; pSivida LTD

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-20261017.htm) filed 2026-10-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-20261019.htm) filed 2026-10-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-20260910.htm) filed 2026-09-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-20260817.htm) filed 2026-08-17
- [10-Q](https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-20260805.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1314102/000119312526324866/eypt-20260730.htm) filed 2026-07-30
- [8-K](https://www.sec.gov/Archives/edgar/data/1314102/000119312526307792/eypt-20260713.htm) filed 2026-07-17

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001314102), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/eyepoint/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "EyePoint (EYPT) news: layoffs", 2026-10-31, https://aibio.space/companies/eyepoint/